Robustness of response: A new measure of response assessment: Its impact on metricies of response in colorectal cancer No significant financial relationships to disclose. This is an ASCO Meeting ...

Salinomycin and paclitaxel silk fibroin nanoparticles incorporated silk fibroin hydrogel for superior inhibition of cancer stem cells and tumor growth. This is an ASCO Meeting Abstract from the 2015 ...

Onivyde (irinotecan liposome) is a prescription drug that’s used to treat certain forms of metastatic pancreatic cancer in adults. Onivyde is given as an intravenous (IV) infusion by your doctor or ...

Prior exposure to conventional irinotecan does not affect survival in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who are subsequently treated with the liposomal formulation ...

Please provide your email address to receive an email when new articles are posted on . The phase 3 randomized study, presented at ASCO Annual Meeting, evaluated the overall response rate of ...

The US Food and Drug Administration (FDA) has approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) in combination with oxaliplatin, fluorouracil, and leucovorin for the first-line ...

Robert Iannone, MD, MSCE, executive vice president of research and development for Jazz Pharmaceuticals, addresses findings of an abstract presented at ASCO 2021 which showed preliminary efficacy of ...